(Total Views: 647)
Posted On: 03/15/2023 11:56:33 AM
Post# of 153988
Re: HHIGambler #133445
Good article, HHIGambler. Thanks to you and misiu for posting.
This caught my eye:
Along with NASH, CytoDyn will focus primarily on oncology. Here, the company will target colorectal cancer and hormone receptor-positive, HER2-negative breast cancer.
CYDY withdrew the following trial on Clinical Trials last month with no participants enrolled:
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT057306...amp;rank=4
Couple of possibilities:
Maybe they are now planning a new trial that will not be a combination.
Maybe plans are ongoing for a partnership for colorectal cancer.
In any event, I thought that it was interesting that Arman called colorectal cancer a focus area while withdrawing their combo trial.
This caught my eye:
Along with NASH, CytoDyn will focus primarily on oncology. Here, the company will target colorectal cancer and hormone receptor-positive, HER2-negative breast cancer.
CYDY withdrew the following trial on Clinical Trials last month with no participants enrolled:
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT057306...amp;rank=4
Couple of possibilities:
Maybe they are now planning a new trial that will not be a combination.
Maybe plans are ongoing for a partnership for colorectal cancer.
In any event, I thought that it was interesting that Arman called colorectal cancer a focus area while withdrawing their combo trial.
(11)
(0)
